Arcellx, INC. (ACLX) — 10-Q Filings

10-Q Filings (6)

• Arcellx's Net Loss Widens to $170.8M on Revenue Drop, R&D Spend — Nov 5, 2025 Risk: high
  Arcellx, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $170.8 million, a substantial rise from $60.3 m
• Arcellx Revenue Jumps 100% on Kite Deal, Net Loss Widens — Aug 7, 2025 Risk: medium
  Arcellx, Inc. reported a significant increase in collaboration revenue for the three months ended June 30, 2025, reaching $10.0 million, up from $5.0 million in
• Arcellx, Inc. Files Q1 2025 10-Q Report — May 8, 2025 Risk: medium
  Arcellx, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. K
• Arcellx Q3 2024 Update: Clinical Progress & Financials — Nov 7, 2024 Risk: medium
  Arcellx, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position, including cash and cash equivalents, and
• Arcellx Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Arcellx, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Ke
• Arcellx, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: medium
  Arcellx, Inc. (ACLX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Arcellx, Inc. reported its financial results for the quarter ended March 31, 2

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX